BWS Financial Inc

BWS provides independent stock specific research focused on companies with distinct value that are going through a special situation where there is a tangible catalyst not priced in. The catalyst can be anything from new product, restructuring, M&A, management change, change in business strategy, etc. BWS’s focus is to understand the change and evaluate the potential return for investors.

BWS utilizes a self formed proprietary approach in discovering stocks by putting great emphasis on deep research. BWS does generate short recommendations following a similar criteria.

Independent Stock Specific Research

ASRT: Generic Risk Extends Timeline, PT $6

ASRT: ASEG Guideline a Significant Positive, PT to $8

ASRT: Updated Q4 Results Puts 2023 in Focus

Founder, BWS Financial Inc

Hamed Khorsand

Founder

Equity Bottom-Up

<ul>
<li>ASRT is not including the recent guideline change at American Society for Gastrointestinal Endoscopy ("ASEG") for using indomethacin as part of their 2023 outlook allows ample room to the upside.</li>
<li>ASRT had previously provided preliminary fourth quarter results. The official numbers were not much different</li>
<li>Indocin has been the core of ASRT’s revenue and free cash flow. The new guidelines could become a game changing event for the drug and ASRT</li>
</ul>


ASRT is not including the recent guideline change at American Society for Gastrointestinal Endoscopy ("ASEG") for using indomethacin as part of their 2023 outlook allows ample room to the upside.
ASRT had previously provided preliminary fourth quarter results. The official numbers were not much different
Indocin has been the core of ASRT’s revenue and free cash flow. The new guidelines could become a game changing event for the drug and ASRT


Assertio Holdings

ASRT: Primed for Growth